Target‐Specific Dermatological Adverse Event Reporting With T‐Cell–Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016–2026
Saikat Mandal, Manideepa Maji, Arkadeep Dhali · 2026
Read Target‐Specific Dermatological Adverse Event Reporting With T‐Cell–Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016–2026 by Saikat Mandal, Manideepa Maji, Arkadeep Dhali (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13527524.txt.
Description
Saikat Mandal and two co-authors mine drug safety reports for skin side effects of a class of cancer antibodies, in a 2026 study. The drugs bind two targets at once and pull T cells onto cancer cells. Rash and severe skin harm are less charted for them than other side effects. The team searched United States and Canadian report banks from 2016 onward, covering ten drugs grouped by target.
Among exposed reports in the United States bank, about six percent noted a skin event, and severe skin reactions were rare. No clear class-wide excess of severe reactions stood up after matching by disease. One drug, aimed at a skin-linked target, drew far more skin reports than the rest. Another showed a hint of very early skin onset on thin data. The authors urge target-aware skin watch in care.
Catalog record
| CREATOR | Saikat Mandal, Manideepa Maji, Arkadeep Dhali |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |